← board
LCTX
distress 3/10 · well-funded / low risk$1.09-1%today-44% from 52w high
Revenue
pre-revenue
Liquidity
$53M
Runway
2.4 yrs
Shares 1y
+9%
Price & events
-33.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
-6.4%
1W
-12.4%
1M
-29.8%
3M
-32.0%
6M
+1.4%
1Y
-2.2%
2Y
-58.8%
5Y
-43.3%
All
Overview
- Market Cap
- $272.98M
- Volume
- 383.19K
- 52 Week Range
- $0.94 – $1.96
- Total Shares
- 249.30M
- Float Shares
- 187.28M
- Short %
- 18.93%
- % Held by Insiders
- 4.93%
- % Held by Institutions
- 47.46%
- RVOL
- 0.22x
- Beta
- 1.51
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 7
- 2026-08-11Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-06-09withdrawalOPC1 · Withdrew application for CIRM grant to support OPC1 clinical development for spinal cord injury.SEC 8-K
- 2025-11-28withdrawalOPC1 · Withdrew CIRM grant application for OPC1 in spinal cord injury; intends to resubmit in January 2026.SEC 8-K
- 2025-11-20partnershipOpRegen · First development milestone achieved under Roche Agreement, triggering $5M payment.SEC 8-K
- 2025-08-22partnershipReSonance (ANPI) · Multi-year research collaboration with WDI for up to $12M to advance preclinical development of auditory neuronal cell transplant program for hearing loss.SEC 8-K
- 2025-01-27fda agreementOpRegen · Shareholders approved issuance of shares and warrants related to OpRegen milestone-linked warrants.SEC 8-K
- 2025-01-27partnershipClosed second tranche of registered direct offering, receiving $6M in gross proceeds.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $6 (+402% upside) · 6 analysts
- 2026-07-14HC Wainwright & Co.Buy
- 2026-05-04D. Boral CapitalBuy
- 2026-04-28Canaccord GenuityBuy
- 2026-03-25B. Riley SecuritiesBuy
- 2026-03-24HC Wainwright & Co.Buy
- 2026-03-06D. Boral CapitalBuy
Competitors
- none identified
Recent news
- 2026-07-18LCTX SEC Filings - Lineage Cell The 10-K, 10-Q, 8-K Forms - Stock Titan
- 2026-07-15Craig-Hallum Maintains Lineage Cell Therapeutics(LCTX.US) With Buy Rating - Moomoo
- 2026-07-15Lineage Therap (LCTX) Gets a Buy from H.C. Wainwright - The Globe and Mail
- 2026-07-13Lineage Cell advances corneal cell therapy program to animal testing - Investing.com
- 2026-07-13Lineage Cell Therapeutics Provides Update On COR1 Cell Therapy Program For Corneal Endothelial Disease - marketscreener.com
- 2026-07-13Lineage Cell Updates on COR1 for Corneal Endothelial Disease Tre - GuruFocus
- 2026-07-13Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease - Business Wire
- 2026-07-13Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease - Business Wire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.